Abingworth — 2015 Investments

2 investments dated 2015 · listed companies and verified rows first · show all

CRISPRcrisprtx.com in 𝕏Series A · Apr 2015 · $35M

CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.

BiotechDeep TechHealthtechZug, CH

Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in

Board seatKurt von Emster· per SEC Form D

Co-investorsAvoro Capital Advisors CLI Ventures Khosla Ventures New Enterprise Associates (NEA)SR One Capital Management Versant Ventures +2 more

Gensight Biologics S.Agensight-biologics.com in 𝕏Series A · Jul 2015 · $42M

GenSight Biologics develops clinical-stage gene therapy treatments, with a lead candidate (GS010/LUMEVOQ) in development for rare genetic diseases.

BiotechDigital HealthHealthtechMedical DevicesParis, FR

Bernard Gilly(Executive Officer, Director)inJean-Philippe Combal(Executive Officer)inThomas Gidoin(Executive Officer)Didier Pruneau(Executive Officer)inNitza Thomasson(Executive Officer)in

BoardFlorent Gros(Director)

Board seatGenghis Lloyd-Harris· per SEC Form D

Co-investorsAgoranov Sofinnova Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.